Besides, A2AR is also located in glutamatergic terminals and controls the release of glutamate from afferent glutamatergic terminals which trigger the activity in the striatum, and A2AR is highly important in the control of voluntary movement [7,8,9], so a lot of research groups have dedicated significant efforts towards the discovery of selective A2AR antagonists for the therapy of PD [10]. This evidence concerns the gene ADORA2A and Parkinson disease.